Understanding how SETD2 inactivation affects lung adenocarcinoma growth
Official title: Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
Funded at University of Pennsylvania · NIH-10989950 · Data updated 2026-11-12
This study is looking at how a gene called SETD2 affects lung adenocarcinoma, a common lung cancer, and will test if certain diets and medications can help slow down tumor growth in patients with this gene issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 10, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $390,999 |
| NIH project number | 5R01CA262619-04 |
| Project ID | NIH-10989950 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have mutations leading to SETD2 inactivation.
✕Less likely to help
Patients with lung adenocarcinoma who do not have SETD2 mutations may not benefit from this research.
What this research studies
This research investigates the role of SETD2 inactivation in lung adenocarcinoma, a common type of lung cancer. It explores how the loss of SETD2 leads to increased tumor cell proliferation through changes in one-carbon metabolism and activation of specific signaling pathways. The study will involve testing dietary interventions and drugs that target the methionine cycle to see if they can effectively reduce tumor growth in patients with SETD2 deficiency. By understanding these mechanisms, the research aims to identify new treatment strategies for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with lung adenocarcinoma that has SETD2 inactivation.
How similar studies have gone: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting potential for success in this approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Feldser, David — University of Pennsylvania
- Study coordinator: Feldser, David
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.